@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAeZ6H2kE8txs-LJbFriKNWveDq31jmqDrOlzqYT2NwOI> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAeZ6H2kE8txs-LJbFriKNWveDq31jmqDrOlzqYT2NwOI#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix sdis: <http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-diseases/> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: hgnc:6018;
    a Protein: .
  
  sub:_2 occursIn: mesh:D009132, mesh:D017667, species:9606;
    rdf:object sub:_1;
    rdf:predicate belv:positiveCorrelation;
    rdf:subject sdis:Type%20II%20diabetes;
    a rdf:Statement .
  
  sub:assertion rdfs:label "path(SDIS:\"Type II diabetes\") positiveCorrelation p(HGNC:IL6)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "1.4" .
  
  sub:_3 prov:value "indicating that IL-6 effects on muscle metabolism may be mediated through increased lipid availability. Decreases in fatty acid oxidation and increased fatty acid uptake have been proposed as possible mechanisms of increased lipid accumulation, which causes insulin resistance, with obesity (48) and diabetes. Thus elevated fasting plasma IL-6 concentrations would be detrimental to insulin action. Serum IL-6 levels are elevated with obesity (57) and diabetes (28) and are negatively related with insulin-stimulated glucose disposal during a euglycemic-hyperinsulinemic clamp (57).";
    prov:wasQuotedFrom pubmed:16020439 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:16020439;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:36.849+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}